defoslimod , CAS No.171092-39-0, Agonist of TLR2;Agonist of TLR4

Item Number
D609793
Grouped product items
SKUSizeAvailabilityPrice Qty
D609793-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,000.90
D609793-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$4,000.90
View related series
TLR2 Agonist TLR4 Agonist

Basic Description

Specifications & PurityMoligand™
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of TLR2;Agonist of TLR4

Associated Targets(Human)

TLR2 Tchem Toll-like receptor 2 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
TLR4 Tchem Toll-like receptor 4 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

INCHI InChI=1S/C52H100N2O20P2/c1-4-7-10-13-16-19-22-25-28-31-38(56)34-42(57)53-45-48(61)47(60)41(72-52(45)74-76(66,67)68)37-69-51-46(49(62)50(40(36-55)71-51)73-75(63,64)65)54-43(58)35-39(32-29-26-23-20-17-14-11-8-5-2)70-44(59)33-30-27-24-21-18-15-12-9-6-3/h38-41,45-52,55-56,60-62H,4-37H2,1-3H3,(H,53,57)(H,54,58)(H2,63,64,65)(H2,66,67,68)/t38-,39+,40-,41-,45-,46-,47-,48-,49-,50-,51-,52-/m1/s1
InChi Key GOWLTLODGKPXMN-MEKRSRHXSA-N
Canonical SMILES CCCCCCCCCCC[C@H](CC(=O)N[C@H]1[C@H](O[C@@H]([C@H]([C@@H]1O)O)CO[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1NC(=O)C[C@@H](OC(=O)CCCCCCCCCCC)CCCCCCCCCCC)O)OP(=O)(O)O)OP(=O)(O)O)O
Isomeric SMILES CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OP(=O)(O)O)O)NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)O)O)O
PubChem CID 656812

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Onier N, Hilpert S, Arnould L, Saint-Giorgio V, Davies JG, Jeannin JF, Jeannin JF.  (1999)  Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats..  Clin Exp Metastasis,  17  (4): (299-306).  [PMID:10545016] [10.1021/op500134e]
2. Brandenburg K, Lindner B, Schromm A, Koch MH, Bauer J, Merkli A, Zbaeren C, Davies JG, Seydel U.  (2000)  Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity..  Eur J Biochem,  267  (11): (3370-7).  [PMID:10824125] [10.1021/op500134e]
3. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C.  (2007)  Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help..  Eur J Pharmacol,  563  (1-3): (1-17).  [PMID:17383632] [10.1021/op500134e]
4. Meraldi V, Audran R, Romero JF, Brossard V, Bauer J, López JA, Corradin G.  (2003)  OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei..  Vaccine,  21  (19-20): (2485-91).  [PMID:12744882] [10.1021/op500134e]
5. Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M.  (2013)  Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors..  BMC Cancer,  13  (13): (172).  [PMID:23547558] [10.1021/op500134e]

Solution Calculators